Ironwood Pharmaceuticals Inc. (IRWD)

17.17
NASDAQ : Health Technology
Prev Close 17.30
Day Low/High 17.02 / 17.43
52 Wk Low/High 12.89 / 21.20
Avg Volume 891.70K
Exchange NASDAQ
Shares Outstanding 139.18M
Market Cap 2.65B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Ironwood Pharmaceuticals Announces FDA Fast Track Designation For Praliciguat For The Treatment Of Heart Failure With Preserved Ejection Fraction (HFpEF)

Ironwood Pharmaceuticals Announces FDA Fast Track Designation For Praliciguat For The Treatment Of Heart Failure With Preserved Ejection Fraction (HFpEF)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.

Ironwood Pharmaceuticals To Present At Upcoming September Investor Conferences

Ironwood Pharmaceuticals To Present At Upcoming September Investor Conferences

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2018 Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 1:55 p.

First Week Of IRWD October 19th Options Trading

First Week Of IRWD October 19th Options Trading

Investors in Ironwood Pharmaceuticals Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IRWD options chain for the new October 19th contracts and identified the following call contract of particular interest.

Approval Of Linzess® Tablets 0.25 Mg In Japan For Additional Indication Of Chronic Constipation

Approval Of Linzess® Tablets 0.25 Mg In Japan For Additional Indication Of Chronic Constipation

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.

Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

Ironwood Pharmaceuticals, Inc. (Nasdaq:IRWD), a commercial biotechnology company, today provided an update on its second quarter 2018 results and recent business activities.

Ironwood Pharmaceuticals To Host Second Quarter 2018 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2018 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2018 investor update conference call and webcast at 8:30 a.

Ironwood Pharmaceuticals Initiates Phase IIIb Study Of Linaclotide In Adult Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood Pharmaceuticals Initiates Phase IIIb Study Of Linaclotide In Adult Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced the initiation of a Phase IIIb clinical trial evaluating the efficacy and safety of linaclotide 290 mcg on multiple abdominal symptoms in addition to pain,...

Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact On Metabolic And Cardiovascular Clinical Endpoints At The American Diabetes Association's 78th Scientific Sessions

Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact On Metabolic And Cardiovascular Clinical Endpoints At The American Diabetes Association's 78th Scientific Sessions

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today presented additional data from an exploratory Phase IIa study of praliciguat (IW-1973) in patients with type 2 diabetes and hypertension during an oral session at the...

Ironwood Pharmaceuticals Initiates Pivotal Phase III Program For IW-3718 In Persistent Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals Initiates Pivotal Phase III Program For IW-3718 In Persistent Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced the initiation of two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD).

Ironwood Pharmaceuticals To Highlight Clinical And Preclinical Data For Praliciguat At The American Diabetes Association's 78th Scientific Sessions

Ironwood Pharmaceuticals To Highlight Clinical And Preclinical Data For Praliciguat At The American Diabetes Association's 78th Scientific Sessions

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company will present clinical and preclinical data for the company's soluble guanylate cyclase (sGC) stimulator praliciguat (IW-1973) during the...

Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation For Olinciguat For The Treatment Of Sickle Cell Disease

Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation For Olinciguat For The Treatment Of Sickle Cell Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.

Ironwood Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Ironwood Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13 th, 2018 at 4:00 p.

Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements In Heartburn And Regurgitation Symptoms In Patients With Persistent GERD At Digestive Disease Week® 2018

Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements In Heartburn And Regurgitation Symptoms In Patients With Persistent GERD At Digestive Disease Week® 2018

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today presented data from a double-blind, placebo-controlled, dose-ranging Phase IIb trial evaluating IW-3718 in persistent gastroesophageal reflux disease (GERD) during a...

Ironwood Pharmaceuticals To Highlight Clinical Data For IW-3718 In Persistent Gastroesophageal Reflux Disease (GERD) At Digestive Disease Week® 2018

Ironwood Pharmaceuticals To Highlight Clinical Data For IW-3718 In Persistent Gastroesophageal Reflux Disease (GERD) At Digestive Disease Week® 2018

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company in collaboration with researchers will present clinical data for IW-3718 during Digestive Disease Week (DDW) in Washington D.

Ironwood Pharmaceuticals Sends Letter To Shareholders Highlighting Director Nominees

Ironwood Pharmaceuticals Sends Letter To Shareholders Highlighting Director Nominees

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotech company, today announced that it has mailed a letter to shareholders highlighting the experience and personal perspectives of the company's director nominees: Lawrence Olanoff, M.

Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed To Unlock Shareholder Value

Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed To Unlock Shareholder Value

Ironwood Pharmaceuticals, Inc.(NASDAQ: IRWD), a commercial biotech company, today announced that it filed an investor presentation with the Securities and Exchange Commission in connection with the company's Annual Meeting of Shareholders scheduled for...

Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Aurobindo Pharma Ltd.

(Graphic: Business Wire)

(Graphic: Business Wire)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that it filed definitive proxy materials with the Securities and Exchange Commission in connection with Ironwood's Annual Meeting of Shareholders on May 31, 2018.

Allergan And Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed To Encourage Sufferers To Get Educated And Take Action

-- AboutYourGut.com Provides Resources and Education Focused on Irritable Bowel Syndrome with Diarrhea (IBS-D), Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) --

Ironwood Pharmaceuticals Announces Intent To Separate Soluble Guanylate Cyclase (sGC) Business From Commercial And Gastrointestinal Business

Ironwood Pharmaceuticals Announces Intent To Separate Soluble Guanylate Cyclase (sGC) Business From Commercial And Gastrointestinal Business

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that its Board of Directors has authorized an intent to separate into two independent, publicly traded companies (Ironwood and "R&D Co.

Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update

Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its first quarter 2018 results and recent business activities.

Ironwood Pharmaceuticals To Present At Upcoming March Investor Conferences

Ironwood Pharmaceuticals To Present At Upcoming March Investor Conferences

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in March: 2018 Cowen and Company 38th Annual Health Care Conference on Monday,...

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2017 Investor Update

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2017 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2017 results and recent business activities.

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2017 Investor Update Call

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2017 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2017 investor update conference call and webcast at 8:30 a.

Ironwood And Allergan Announce Settlement With Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood And Allergan Announce Settlement With Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with wholly-owned subsidiaries of Sun Pharmaceutical Industries Ltd.

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 36 th Annual J.

First Week Of August 2018 Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week Of August 2018 Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc saw new options become available this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ironwood Pharmaceuticals Initiates Phase II Clinical Trial Of SGC Stimulator IW-1701 In Patients With Sickle Cell Disease

Ironwood Pharmaceuticals Initiates Phase II Clinical Trial Of SGC Stimulator IW-1701 In Patients With Sickle Cell Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the initiation of STRONG-SCD, a Phase II clinical trial evaluating once-daily IW-1701, an orally administered soluble...

TheStreet Quant Rating: D (Sell)